Recursion Pharmaceuticals, Inc.
RXRX
$4.51
$0.194.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -162.25M | -171.90M | -202.49M | -178.91M | -95.84M |
| Total Depreciation and Amortization | 21.04M | 23.85M | 19.33M | 12.95M | 7.20M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 50.15M | 36.48M | 57.05M | 44.48M | 29.68M |
| Change in Net Operating Assets | -26.30M | 35.15M | -5.85M | 6.05M | -264.00K |
| Cash from Operations | -117.36M | -76.42M | -131.96M | -115.43M | -59.23M |
| Capital Expenditure | -243.00K | -3.15M | -1.83M | -1.30M | -4.56M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 277.10M | -- |
| Divestitures | 0.00 | 0.00 | -4.44M | -- | -- |
| Other Investing Activities | -2.31M | -2.66M | -1.00M | -350.00K | 0.00 |
| Cash from Investing | -2.55M | -5.81M | -7.27M | 275.46M | -4.56M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.13M | -2.08M | -2.05M | -2.10M | -2.29M |
| Issuance of Common Stock | 253.47M | 102.74M | 42.57M | 12.74M | 18.75M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -3.00M | -- | -- | -- |
| Cash from Financing | 251.34M | 97.66M | 40.53M | 10.64M | 16.46M |
| Foreign Exchange rate Adjustments | 1.87M | 9.26M | 4.83M | -3.47M | 403.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 133.30M | 24.69M | -93.87M | 167.19M | -46.92M |